FlyBase Allele Report: Hsap\FUS[UAS.Tag:HA]

General Information

Symbol

Hsap\FUS^UAS.Tag:HA

Species

H. sapiens

Name

FlyBase ID

FBal0261073

Feature type

allele

Associated gene

Hsap\FUS

Associated Insertion(s)

Carried in Construct

P{UAS-hFUS.HA}

Also Known As

UAS-HA-FUS, FUS-WT, FUS WT, UAS-FUS WT, UAS-FUS

Key Links

Transgenic product class

wild_type

(Lanson et al., 2011)

Mutagen

in vitro construct

Nature of the Allele

Transgenic product class

wild_type

(Lanson et al., 2011)

Mutagen

in vitro construct

(Lanson et al., 2011)

Progenitor genotype

Carried in construct

P{UAS-hFUS.HA}

Cytology

Description

UAS regulatory sequences drive expression of wild-type Hsap\FUS coding sequences.

(Lanson et al., 2011)

Allele components

Component

Use(s)

Regulatory region(s)

UAS

binary expression system - regulatory region

Encoded product / tool

Hsap\FUS

Tagged with

Tag:HA

epitope tag

Mutations Mapped to the Genome

Curation Data

Type

Location

Additional Notes

References

Variant Molecular Consequences

Associated Sequence Data

DDBJ / EMBL / GenBank

DNA sequence

Protein sequence

UniProtKB/Swiss-Prot

UniProtKB/TrEMBL

Expression Data

Reporter Expression

Additional Information

Statement

Reference

Marker for

Reflects expression of

Reporter construct used in assay

Human Disease Associations

Disease Ontology (DO) Annotations

Models Based on Experimental Evidence ( 1 )

Disease

Evidence

References

model of amyotrophic lateral sclerosis

CEA

(Machamer et al., 2014, Scaramuzzino et al., 2013)

model of neurodegenerative disease

CEA

(Uechi et al., 2018)

model of amyotrophic lateral sclerosis type 6

CEC

(Casci et al., 2019)

CEA

(Fortuna et al., 2021, Lin et al., 2021, Guo et al., 2018, Marrone et al., 2018)

Modifiers Based on Experimental Evidence ( 1 )

Disease

Interaction

References

model of neurodegenerative disease

is exacerbated by CG5445^NIG.5445R

(Uechi et al., 2018)

is ameliorated by CG5445^UAS.cUa

(Uechi et al., 2018)

model of amyotrophic lateral sclerosis

is exacerbated by Art1^KK101196

(Scaramuzzino et al., 2013)

model of amyotrophic lateral sclerosis type 6

is ameliorated by Smn^UAS.Tag:FLAG

(Casci et al., 2019)

is exacerbated by mbl^C.UAS

(Casci et al., 2019)

is exacerbated by Smn^GL00581

(Casci et al., 2019)

is ameliorated by mbl^GD13374

(Casci et al., 2019)

is ameliorated by mbl^KK107778

(Casci et al., 2019)

is ameliorated by Tnpo^GD33

(Guo et al., 2018)

is ameliorated by Nup214^GD11084

(Lin et al., 2021)

is ameliorated by Nup54^KK102105

(Lin et al., 2021)

is ameliorated by Nup62^KK108318

(Lin et al., 2021)

is exacerbated by Nup62^UAS.cAa

(Lin et al., 2021)

is ameliorated by Nup98-96^KK100388

(Lin et al., 2021)

is exacerbated by Rm62^unspecified

(Fortuna et al., 2021)

is ameliorated by abs^KK101165

(Fortuna et al., 2021)

is ameliorated by Rm62^UAS.cUa

(Fortuna et al., 2021)

is ameliorated by vas^KK100929

(Fortuna et al., 2021)

is exacerbated by Rm62^RNAi.UAS.cUa

(Fortuna et al., 2021)

exacerbates neurodegenerative disease

modeled by Zzzz\CGG^90.UAS.EGFP

(He et al., 2014)

Comments on Models/Modifiers Based on Experimental Evidence ( 0 )

Disease-implicated variant(s)

Phenotypic Data

Phenotypic Class

abnormal eye color | progressive, with Scer\GAL4^GMR.PU

(Uechi et al., 2018)

abnormal locomotor behavior | adult stage, with Scer\GAL4^{elav.Switch.PO}

(Fortuna et al., 2021)

abnormal locomotor behavior | larval stage, with Scer\GAL4^Toll-6-D42

(Casci et al., 2019)

abnormal locomotor behavior | RU486 conditional, with Scer\GAL4^{elav.Switch.PO}

(Lanson et al., 2011)

abnormal neuroanatomy | larval stage, with Scer\GAL4^Toll-6-D42

(Casci et al., 2019)

abnormal neuroanatomy | third instar larval stage, with Scer\GAL4^VGlut1-OK371

(Machamer et al., 2014)

abnormal neurophysiology, with Scer\GAL4^VGlut1-OK371

(Shahidullah et al., 2013)

abnormal neurophysiology | third instar larval stage, with Scer\GAL4^VGlut1-OK371

(Machamer et al., 2014)

majority die during pharate adult stage, with Scer\GAL4^VGlut1-OK371

(Machamer et al., 2014)

short lived, with Scer\GAL4^{elav.Switch.PO}

(Fortuna et al., 2021)

short lived | RU486 conditional, with Scer\GAL4^{elav.Switch.PO}

(Lanson et al., 2011)

visible, with Scer\GAL4^GMR.PF

(Daigle et al., 2013)

visible | adult stage, with Scer\GAL4^GMR.PF

(Ramesh et al., 2020, Scaramuzzino et al., 2013)

visible | adult stage, with Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

visible | adult stage | progressive, with Scer\GAL4^GMR.PF

(Casci et al., 2019)

visible | adult stage | progressive, with Scer\GAL4^GMR.PU

(Uechi et al., 2018)

Phenotype Manifest In

Detailed Description

Statement

Reference

The expression of Hsap\FUS^UAS.Tag:HA under the control of Scer\GAL4^GMR.PU results in eye degeneration. Adulthood-only expression under the control of Scer\GAL4^{elav.Switch.PO} and induced by RU486 results in a decrease in climbing ability.

(Fortuna et al., 2021)

The expression of Hsap\FUS^UAS.Tag:HA under the control of Scer\GAL4^GMR.PF results in external eye degeneration.

(Ramesh et al., 2020)

Expressing Hsap\FUS^UAS.Tag:HA under the control of Scer\GAL4^GMR.PF results in eye degeneration: rough eye with loss of pigmentation; retinal degradation, length reduction, and separation from the lamina at the basal membrane. There is a decrease in adult climbing activity.

Expressing Hsap\FUS^UAS.Tag:HA under the control of Scer\GAL4^Toll-6-D42 leads to more satellite boutons (but no change in the number of mature boutons or boutons size) in the larval neuromuscular junction.

(Casci et al., 2019)

At day one post eclosion flies expressing Hsap\FUS^{Scer\UAS.T:Ivir\HA1} under the control of Scer\GAL4^GMR.PU do not display any obvious eye defects but as they age the begin to show mild pigmentation loss.

(Uechi et al., 2018)

Expression of Hsap\FUS^{Scer\UAS.T:Ivir\HA1} in motor neurons under the control of Scer\GAL4^VGlut-OK371 has no significant effect on larval motility.

Expression of Scer\GAL4^VGlut-OK371>Hsap\FUS^{Scer\UAS.T:Ivir\HA1} results in an approximately three-fold increase in the number of inter-bouton regions at third instar larval neuromuscular junctions compared with wild-type.

Scer\GAL4^VGlut-OK371>Hsap\FUS^{Scer\UAS.T:Ivir\HA1}-expressing animals display an approximately 50% reduction in the number of presynaptic active zones compared with wild-type.

Compared with wild-type, third instar larvae expressing Hsap\FUS^{Scer\UAS.T:Ivir\HA1} under the control of Scer\GAL4^VGlut-OK371 display an approximately 25% reduction in evoked excitatory junction potential (EJP) amplitude. The reduction of quantal size in these animals reaches statistical significance. Compared with wild-type, a greater than two-fold increase in mEJP frequency is observed in the transgenic flies. Hsap\FUS^{Scer\UAS.T:Ivir\HA1}-expression causes a significant reduction in both rise and decay time in EJP waveform kinetics.

(Machamer et al., 2014)

Expression of Hsap\FUS^{Scer\UAS.T:Ivir\HA1} under the control of Scer\GAL4^GMR.PF results in a mild eye degenerative phenotype.

(Scaramuzzino et al., 2013)

Over-shooting action potentials can be evoked in neurons expressing Hsap\FUS^{Scer\UAS.T:Ivir\HA1} under the control of Scer\GAL4^VGlut-OK371 by injection of depolarising current via a recording electrode. Neurons fire repetitively in response to a sustained stimulus, with no apparent accommodation. In contrast to the evoked cell body action potentials, there is no statistically significant difference in the frequency of the spontaneous orthodromic action potentials recorded from the axons of Hsap\FUS^{Scer\UAS.T:Ivir\HA1}-expressing larvae and wild-type.

Neuronal expression of Hsap\FUS^{Scer\UAS.T:Ivir\HA1} under the control of Scer\GAL4^VGlut-OK371 appears to have little effect on the fast inward currents evoked by membrane depolarisation.

Pre-synaptic expression of Hsap\FUS^{Scer\UAS.T:Ivir\HA1} (under the control of Scer\GAL4^VGlut-OK371) does not influence the amplitude of the excitatory junction current.

The structure of presynaptic active zones is unaffected in flies expressing Hsap\FUS^{Scer\UAS.T:Ivir\HA1} under the control of Scer\GAL4^VGlut-OK371.

(Shahidullah et al., 2013)

Expression of Hsap\FUS^{Scer\UAS.T:Ivir\HA1} in the developing eye under the control of Scer\GAL4^GMR.PF results in a very mild eye degeneration phenotype, correlated with vacuolar neurodegeneration with severe disruption of the retinal organization and thinning of the retina.

Induction of Hsap\FUS^{Scer\UAS.T:Ivir\HA1} expression in adult neurons under the control of Scer\GAL4^{elav.Switch.PO} results in a reduction in life span compared to controls. These flies start dying after 10 days of RU486 treatment. The overall reduction in life span is similar in males and females with all of the male flies dead in 29 days.

Induction of Hsap\FUS^{Scer\UAS.T:Ivir\HA1} expression in adult neurons under the control of Scer\GAL4^{elav.Switch.PO} causes an age-dependent decline in climbing ability. At day 20 approximately 41% of these flies treated with RU486 are able to climb.

(Lanson et al., 2011)

External Data

Linkouts

Interactions

Show genetic interaction network for Enhancers & Suppressors

Phenotypic Class

Enhanced by

Statement

Reference

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has visible | adult stage phenotype, enhanceable by bel^GD1324, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has visible | adult stage phenotype, enhanceable by Rm62^RNAi.UAS.cUa, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has visible | adult stage phenotype, enhanceable by Rm62^unspecified

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has visible | adult stage phenotype, enhanceable by CG10077^RNAi.UAS.cUa, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has visible | adult stage phenotype, enhanceable by mbl^C.UAS, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has visible | adult stage phenotype, enhanceable by Smn^UAS.Tag:FLAG, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has visible | adult stage | progressive phenotype, enhanceable by CG5445^NIG.5445R, Scer\GAL4^GMR.PU

(Uechi et al., 2018)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has abnormal eye color | progressive phenotype, enhanceable by CG5445^NIG.5445R, Scer\GAL4^GMR.PU

(Uechi et al., 2018)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has visible | adult stage phenotype, enhanceable by Art1^KK101196, Scer\GAL4^GMR.PF

(Scaramuzzino et al., 2013)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has increased cell death phenotype, enhanceable by Hsap\TARDBP^{M337V.UAS.Tag:MYC}, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has increased cell death phenotype, enhanceable by Hsap\TARDBP^UAS.Tag:MYC, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Suppressed by

Statement

Reference

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^{elav.Switch.PO} has abnormal locomotor behavior | adult stage | RU486 conditional phenotype, suppressible by Rm62^UAS.cUa, Scer\GAL4^{elav.Switch.PO}

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^{elav.Switch.PO} has short lived | RU486 conditional phenotype, suppressible by Rm62^UAS.cUa, Scer\GAL4^{elav.Switch.PO}

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has visible | adult stage phenotype, suppressible by abs^KK101165, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has visible | adult stage phenotype, suppressible by Rm62^UAS.cUa, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^Toll-6-D42 has abnormal neuroanatomy | larval stage phenotype, suppressible by mbl^KK107778, Scer\GAL4^Toll-6-D42

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has visible | adult stage phenotype, suppressible by Df(2R)Exel6066/+

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has visible | adult stage phenotype, suppressible by Df(2R)BSC154/+

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has visible | adult stage | progressive phenotype, suppressible by mbl^KK107778, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has visible | adult stage phenotype, suppressible by Smn^GL00581, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has visible | adult stage | progressive phenotype, suppressible by CG5445^UAS.cUa, Scer\GAL4^GMR.PU

(Uechi et al., 2018)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has abnormal eye color | progressive phenotype, suppressible by CG5445^UAS.cUa, Scer\GAL4^GMR.PU

(Uechi et al., 2018)

Enhancer of

Statement

Reference

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF is an enhancer of increased cell death phenotype of Hsap\TARDBP^UAS.Tag:MYC, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF is an enhancer of increased cell death phenotype of Hsap\TARDBP^{M337V.UAS.Tag:MYC}, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Phenotype Manifest In

Enhanced by

Statement

Reference

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has eye phenotype, enhanceable by bel^GD1324, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has eye phenotype, enhanceable by Rm62^RNAi.UAS.cUa, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has eye phenotype, enhanceable by Rm62^unspecified

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has eye phenotype, enhanceable by CG10077^RNAi.UAS.cUa, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has eye phenotype, enhanceable by mbl^C.UAS, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has retina phenotype, enhanceable by mbl^C.UAS, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has eye phenotype, enhanceable by Smn^UAS.Tag:FLAG, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has eye | progressive phenotype, enhanceable by CG5445^NIG.5445R, Scer\GAL4^GMR.PU

(Uechi et al., 2018)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has eye | adult stage phenotype, enhanceable by Art1^KK101196, Scer\GAL4^GMR.PF

(Scaramuzzino et al., 2013)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has ommatidium phenotype, enhanceable by Hsap\TARDBP^{M337V.UAS.Tag:MYC}, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has eye phenotype, enhanceable by Hsap\TARDBP^UAS.Tag:MYC, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has ommatidium phenotype, enhanceable by Hsap\TARDBP^UAS.Tag:MYC, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has eye phenotype, enhanceable by Hsap\TARDBP^{M337V.UAS.Tag:MYC}, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Suppressed by

Statement

Reference

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has eye phenotype, suppressible by abs^KK101165, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has eye phenotype, suppressible by Rm62^UAS.cUa, Scer\GAL4^GMR.PU

(Fortuna et al., 2021)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^Toll-6-D42 has embryonic/larval neuromuscular junction | larval stage phenotype, suppressible by mbl^KK107778, Scer\GAL4^Toll-6-D42

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has retina phenotype, suppressible by mbl^KK107778, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has eye phenotype, suppressible by Smn^GL00581, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^Toll-6-D42 has NMJ bouton | larval stage phenotype, suppressible by mbl^KK107778, Scer\GAL4^Toll-6-D42

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has eye phenotype, suppressible by Df(2R)Exel6066/+

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has eye phenotype, suppressible by Df(2R)BSC154/+

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF has eye phenotype, suppressible by mbl^KK107778, Scer\GAL4^GMR.PF

(Casci et al., 2019)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PU has eye | progressive phenotype, suppressible by CG5445^UAS.cUa, Scer\GAL4^GMR.PU

(Uechi et al., 2018)

Enhancer of

Statement

Reference

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF is an enhancer of eye phenotype of Hsap\TARDBP^UAS.Tag:MYC, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF is an enhancer of ommatidium phenotype of Hsap\TARDBP^UAS.Tag:MYC, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF is an enhancer of eye phenotype of Hsap\TARDBP^{M337V.UAS.Tag:MYC}, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Hsap\FUS^UAS.Tag:HA, Scer\GAL4^GMR.PF is an enhancer of ommatidium phenotype of Hsap\TARDBP^{M337V.UAS.Tag:MYC}, Scer\GAL4^GMR.PF

(Lanson et al., 2011)

Additional Comments

Genetic Interactions

Statement

Reference

Xenogenetic Interactions

Statement

Reference

The age-dependent eye pigmentation loss characteristic for adult flies expressing Hsap\FUS^{Scer\UAS.T:Ivir\HA1} under the control of Scer\GAL4^GMR.PU is exacerbated by co-expression of CG5445^NIG.5445R and ameliorated by co-expression of CG5445^Scer\UAS.cUa.

(Uechi et al., 2018)

Co-expression of Art1^KK101196 enhances the eye degeneration phenotype seen in flies expressing Hsap\FUS^{Scer\UAS.T:Ivir\HA1} under the control of Scer\GAL4^GMR.PF.

(Scaramuzzino et al., 2013)

Co-expression of Hsap\FUS^{Scer\UAS.T:Ivir\HA1} and Hsap\TARDBP^Scer\UAS.cRa in the developing eye under the control of Scer\GAL4^GMR.PF leads to moderate eye degeneration.

Co-expression of Hsap\FUS^{Scer\UAS.T:Ivir\HA1} and Hsap\TARDBP^{M337V.Scer\UAS} in the developing eye under the control of Scer\GAL4^GMR.PF leads to severe eye degeneration.

(Lanson et al., 2011)

Complementation and Rescue Data

Comments

Images (0)

Mutant

Wild-type

Stocks (0)

Notes on Origin

Discoverer

External Crossreferences and Linkouts ( 0 )

Synonyms and Secondary IDs (2)

Reported As

Symbol Synonym

Hsap\FUS^{Scer\UAS.T:Ivir\HA1}

Hsap\FUS^UAS.Tag:HA

Name Synonyms

Secondary FlyBase IDs

References (15)

Report Sections

Open Close